BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19590950)

  • 21. The prognostic significance of B lymphocytes in invasive carcinoma of the breast.
    Mahmoud SM; Lee AH; Paish EC; Macmillan RD; Ellis IO; Green AR
    Breast Cancer Res Treat; 2012 Apr; 132(2):545-53. PubMed ID: 21671016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.
    Goto Y; Koyanagi K; Narita N; Kawakami Y; Takata M; Uchiyama A; Nguyen L; Nguyen T; Ye X; Morton DL; Hoon DS
    J Invest Dermatol; 2010 Jan; 130(1):221-9. PubMed ID: 19587692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
    Pinheiro C; Sousa B; Albergaria A; Paredes J; Dufloth R; Vieira D; Schmitt F; Baltazar F
    Histol Histopathol; 2011 Oct; 26(10):1279-86. PubMed ID: 21870331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
    Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
    BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
    Rodríguez-Pinilla SM; Sarrió D; Honrado E; Moreno-Bueno G; Hardisson D; Calero F; Benítez J; Palacios J
    J Clin Pathol; 2007 Sep; 60(9):1006-12. PubMed ID: 17105822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
    Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
    Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
    Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Lee AH; Ellis IO
    Histopathology; 2007 Mar; 50(4):434-8. PubMed ID: 17448018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer.
    Agboola AO; Ebili HO; Iyawe VO; Banjo AA; Salami BS; Rakha EA; Nolan C; Ellis IO; Green AR
    Malays J Pathol; 2016 Aug; 38(2):83-92. PubMed ID: 27568664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
    Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
    Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
    Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
    BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
    Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
    Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.